Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.FBRX · Entity 9529 | Director | January 13, 2021 | January 14, 2021 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date January 13, 2021 · Filed January 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,358 |
Reported balance
After 2021-01-13 transaction · row 1
1 source rowRow 1 · 2021-01-13 · Exercise / conversion · Acquired 500 · Balance 2,358 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.59 · Expires 2021-06-15 | Direct | 0 |
Reported balance
After 2021-01-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-13 · Exercise / conversion · Disposed 500 · Balance 0 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. The option originally covered 7,500 shares pre 15-to-1 reverse stock split which became effective on June 15, 2020. F2: The Form 4 filed October 4, 2019 incorrectly reported the Expiration Date as October 3, 2029. The correct Expiration Date is June 15, 2021. |
| Common StockSEC Table I · non-derivative | IndirectBy Thomas Eric Darcy and Janet E. Darcy, Trustees of the Darcy Family Trust dated September 21, 2001 | 24,637 |
Reported balance
Holding disclosure · report date 2021-01-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 24,637 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. The option originally covered 7,500 shares pre 15-to-1 reverse stock split which became effective on June 15, 2020.
F2: The Form 4 filed October 4, 2019 incorrectly reported the Expiration Date as October 3, 2029. The correct Expiration Date is June 15, 2021.
Viracta Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2034-06-20 | Direct | 50,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 24, 2024 19:46 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000950170-24-077000 · ownership.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 18:22 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036011 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:56 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-035959 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:16 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001209191-21-023657 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-26 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 1, 2021 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 19:17 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000899243-21-002094 · doc4.xml · derivative · entry 3 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2021-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. The option originally covered 7,500 shares pre 15-to-1 reverse stock split which became effective on June 15, 2020. F2 · derivative.expiration_date: The Form 4 filed October 4, 2019 incorrectly reported the Expiration Date as October 3, 2029. The correct Expiration Date is June 15, 2021. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 19:17 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 500 | $9.59 | $4,793.25 |
DisclosureSEC source: 0000899243-21-002094 · doc4.xml · nonDerivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 17:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantCommon Stock | 1,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036700 · doc4.xml · nonDerivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,858 F1 · shares: On January 9, 2020, the Reporting Person was granted a restricted stock unit award under the Issuer's 2017 Equity Incentive Plan subject to satisfaction of certain performance conditions that were established at the time of the Board's approval of the award on January 9, 2020. The performance conditions were satisfied on June 15, 2020. F2 · shares: Reflects a 15-to-1 reverse stock split which became effective on June 15, 2020. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 20:27 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052617 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:29 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033663 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:39 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039406 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| April 12, 2017 Filed Apr 12, 2017 20:55 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 4,528 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026748 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,528 Underlying: Common Stock · 4,528 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.